ATE512365T1 - Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen - Google Patents

Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen

Info

Publication number
ATE512365T1
ATE512365T1 AT05779948T AT05779948T ATE512365T1 AT E512365 T1 ATE512365 T1 AT E512365T1 AT 05779948 T AT05779948 T AT 05779948T AT 05779948 T AT05779948 T AT 05779948T AT E512365 T1 ATE512365 T1 AT E512365T1
Authority
AT
Austria
Prior art keywords
injury
map
neural injury
diagnostic biomarkers
proteolytic products
Prior art date
Application number
AT05779948T
Other languages
German (de)
English (en)
Inventor
Ka-Wang Wang
Ronald Hayes
Ming-Chen Liu
Monika Oli
Original Assignee
Univ Florida
Banyan Biomarkers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Banyan Biomarkers filed Critical Univ Florida
Application granted granted Critical
Publication of ATE512365T1 publication Critical patent/ATE512365T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/117497—Automated chemical analysis with a continuously flowing sample or carrier stream
    • Y10T436/118339—Automated chemical analysis with a continuously flowing sample or carrier stream with formation of a segmented stream
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
AT05779948T 2004-04-15 2005-04-15 Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen ATE512365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56281904P 2004-04-15 2004-04-15
PCT/US2005/013045 WO2005113798A2 (en) 2004-04-15 2005-04-15 Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining

Publications (1)

Publication Number Publication Date
ATE512365T1 true ATE512365T1 (de) 2011-06-15

Family

ID=35428934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05779948T ATE512365T1 (de) 2004-04-15 2005-04-15 Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen

Country Status (8)

Country Link
US (2) US7456027B2 (US07456027-20081125-C00001.png)
EP (1) EP1747282B1 (US07456027-20081125-C00001.png)
JP (1) JP4885122B2 (US07456027-20081125-C00001.png)
AT (1) ATE512365T1 (US07456027-20081125-C00001.png)
AU (1) AU2005245785B2 (US07456027-20081125-C00001.png)
CA (1) CA2578680C (US07456027-20081125-C00001.png)
ES (1) ES2367311T3 (US07456027-20081125-C00001.png)
WO (1) WO2005113798A2 (US07456027-20081125-C00001.png)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207033B1 (en) * 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US7883858B2 (en) * 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
ES2732071T3 (es) * 2005-04-01 2019-11-20 Univ Florida Biomarcadores de lesiones hepáticas
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
CA2636990A1 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases
EP1840574A1 (en) 2006-03-30 2007-10-03 Institut Pasteur Use of the alpha chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases
WO2007140972A1 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Transgelin-3 as biomarker for alzheimer's disease
WO2008079407A1 (en) * 2006-12-26 2008-07-03 Brigham Young University Serum proteomics system and associated methods
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
WO2008097618A1 (en) * 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
AU2013200258B2 (en) * 2007-09-13 2016-06-09 Peptcell Limited Peptide sequences and compositions
WO2009048597A1 (en) * 2007-10-10 2009-04-16 Tenera Technology, Llc Measurement of protease activity in post-mortem meat samples
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP2105742A1 (en) * 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C
EP4235181A3 (en) * 2008-08-11 2024-02-28 Banyan Biomarkers Inc Biomarker detection process and assay of neurological condition
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2010030697A1 (en) * 2008-09-09 2010-03-18 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
IT1392238B1 (it) * 2008-12-02 2012-02-22 Fond Santa Lucia Uso della caspasi-3 per la malattia dell'alzheimer
US7952068B2 (en) 2008-12-16 2011-05-31 Quest Diagnostics Investments Incorporated Methods for detecting catecholamines by mass spectrometry
EP2293072A1 (en) * 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
JP5909447B2 (ja) 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
EP2531224B1 (en) 2010-01-26 2019-06-05 Bioregency, Inc. Compositions and methods relating to argininosuccinate synthetase
AU2011229918B2 (en) * 2010-03-24 2015-02-05 Parker Proteomics, Llc Methods for conducting genetic analysis using protein polymorphisms
AU2011235892B2 (en) * 2010-04-01 2016-07-07 Banyan Biomarkers, Inc. Markers and assays for detection of neurotoxicity
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
SG2014007454A (en) 2010-08-13 2014-07-30 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
US9891232B2 (en) 2010-11-09 2018-02-13 Sarcotein Diagnostics, Llc BIN1 expression as a marker of skeletal muscle mass and neurological conditions
US9612306B2 (en) * 2010-11-26 2017-04-04 Brigham And Women's Hospital, Inc. Method for assessing repetitive head injuries with two-dimensional magnetic resonance spectroscopy
KR101333207B1 (ko) * 2011-07-13 2013-11-26 부산대학교 산학협력단 자궁내막증과 연관된 유전자 마커 및 이의 용도
CA2850178C (en) 2011-09-30 2020-02-25 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2013138509A1 (en) 2012-03-13 2013-09-19 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20140024053A1 (en) * 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
KR20150091389A (ko) * 2012-12-03 2015-08-10 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제의 헤테로사이클릭 억제제에 의한 암 치료
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
DE102012223378A1 (de) * 2012-12-17 2014-06-18 Charité - Universitätsmedizin Berlin In-vitro Verfahren und Kit zur Diagnose von akutem Koronarsyndrom
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10235339B2 (en) 2013-02-19 2019-03-19 Keysight Technologies, Inc. Digital measurement instrument triggered by signal pattern
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
WO2015192014A1 (en) 2014-06-13 2015-12-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2015191825A1 (en) * 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
AU2015300825B2 (en) 2014-08-07 2019-10-10 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
KR102328327B1 (ko) 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
US20170335395A1 (en) * 2014-10-27 2017-11-23 The Trustees Of The University Of Pennsylvania A parkinson's disease diagnostic biomarker panel
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3265811B1 (en) 2015-03-02 2022-10-26 Sarcotein Diagnostics LLC 13+/17+ bin1 expression as a marker of cardiac disorders
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
WO2017027685A2 (en) * 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
EP3387430A4 (en) * 2015-12-11 2019-08-14 Expression Pathology, Inc. SRM / MRM DOSINGS
EP3452828A4 (en) * 2016-05-06 2019-12-04 Nanosomix Inc. BIOMARKERS OF SYNAPTIC PROTEINS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINE INHIBITORS
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
CA3078725A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
BR112019025313A2 (pt) 2017-05-30 2020-06-23 Abbott Laboratories Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019018545A1 (en) 2017-07-18 2019-01-24 The Research Foundation For The State University Of New York BIOMARKERS OF INTRACRANIAL ANEVISM
RU2668534C1 (ru) * 2017-07-18 2018-10-01 Общество с ограниченной ответственностью "ДРД" Диагностический набор реагентов для выявления хронических патологий мозга ишемического генеза
EA202090555A1 (ru) 2017-08-22 2020-06-08 Байоджен Ма Инк. Фармацевтические композиции, содержащие антитела к бета-амилоиду
CN107976481B (zh) * 2017-11-01 2020-04-07 广西壮族自治区食品药品检验所 一种中药材中钪含量的检测方法
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
EP4065986A4 (en) * 2019-11-26 2023-11-15 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR DETECTING AND MANAGING CARDIOVASCULAR DISEASES
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用
BR102021020613A2 (pt) * 2021-10-14 2023-04-18 Universidade Federal Do Rio De Janeiro Método de investigação proteômica em amostra para diagnóstico da rabdomiólise e kits para realização do mesmo
US11928221B2 (en) 2021-11-29 2024-03-12 Bank Of America Corporation Source code clustering for automatically identifying false positives generated through static application security testing
US11941115B2 (en) 2021-11-29 2024-03-26 Bank Of America Corporation Automatic vulnerability detection based on clustering of applications with similar structures and data flows
CN116297952B (zh) * 2023-03-10 2023-10-31 山东省食品药品检验研究院 一种基于肽组学的用于海马物种鉴别的肽生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118606A (en) 1988-09-02 1992-06-02 The Regents Of The University Of California Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
US5912121A (en) * 1992-12-11 1999-06-15 Bringham And Women's Hospital Methods for detecting mutations associated with hypertrophic cardiomyopathy
US5536639A (en) 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
WO1998003190A1 (en) * 1996-07-19 1998-01-29 Neurotrauma Therapeutics, Inc. Calpain inhibitors for the treatment of traumatic brain injury
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
US7384751B1 (en) * 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
EP1137668A1 (en) 1998-12-09 2001-10-04 Frank P. Zemlan A method for detecting neuronal cell damage by quantification of map-2 levels in biological fluids
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US6819325B2 (en) * 2000-03-07 2004-11-16 Microsoft Corporation API communications for vertex and pixel shaders
US20030040660A1 (en) 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2004025298A1 (en) * 2002-09-11 2004-03-25 University Of Florida Analyzing nerve cell damage
US7196169B2 (en) * 2002-10-11 2007-03-27 Queen's University At Kingston Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
DE602004022645D1 (de) * 2003-03-31 2009-10-01 Univ Florida Beurteilung von nervenschäden anhand von blutproben
US20050202508A1 (en) * 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
EP2207033B1 (en) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2732071T3 (es) 2005-04-01 2019-11-20 Univ Florida Biomarcadores de lesiones hepáticas
US7398484B2 (en) * 2005-04-27 2008-07-08 Microsoft Corporation Memory efficient array transposition via multi pass tiling

Also Published As

Publication number Publication date
JP4885122B2 (ja) 2012-02-29
AU2005245785A2 (en) 2005-12-01
US7456027B2 (en) 2008-11-25
WO2005113798A3 (en) 2008-10-23
EP1747282A4 (en) 2009-11-11
ES2367311T3 (es) 2011-11-02
WO2005113798A2 (en) 2005-12-01
JP2007535318A (ja) 2007-12-06
AU2005245785A1 (en) 2005-12-01
AU2005245785B2 (en) 2011-04-07
EP1747282B1 (en) 2011-06-08
US20050260697A1 (en) 2005-11-24
CA2578680C (en) 2011-06-14
US20090317805A1 (en) 2009-12-24
CA2578680A1 (en) 2005-12-01
US8298835B2 (en) 2012-10-30
EP1747282A2 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
ATE512365T1 (de) Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen
WO2005106038A3 (en) Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2007060471A3 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
BR112017025773A2 (pt) métodos de diagnóstico e tratamento de câncer
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2007076523A3 (en) Markers and methods for assessing and treating psoriasis and related disorders
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2009117122A8 (en) Genetic analysis
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2006086242A3 (en) Mild osteoarthritis biomarkers and uses thereof
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
ATE404118T1 (de) System für kontinuierliche leistungstests
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
WO2007019312A3 (en) Methods for characterizing and treating cognitive impairment in aging and disease
WO2003046578A3 (en) Method for the assessment and prognosis of sarcoidosis
TW200716764A (en) Bladder cancer biomarkers and uses thereof
WO2007134028A3 (en) Biomarkers for depression and methods using the same
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
WO2004026107A3 (en) Kits and methods for assessing skin health

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties